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hydantoins, succinimides, oxazolidinediones) or closely

ARYL SUBSTITUTED

related structure (primidone). On the other hand, the
dicarboximide function, which contributes to the inher
ent hypnotic and sedative activity of the barbiturates
and related compounds, is absent in the triazolines.

1H-4,5-DIHYDRO-1,2,3-TRIAZOLES AS
ANTICONVULSANTS
CROSS REFERENCE TO RELATED
APPLICATIONS
This application is a continuation-in-part of parent

Triazolines including A2-1,2,3-triazolines, are known
to some extent in the prior art, through applicant’s own
publications of work in this area. None of the triazo
lines, however, has been suggested heretofore for use as

application Ser. No. 476,792, ?led Mar. 18, 1983, now
US. Pat. No. 4,511,572, issued Apr. 16, 1985.

anticonvulsants.
As indicated, the present applicant has published a

TECHNICAL FIELD

number of papers involving her work on triazolines.

This invention relates to A2-1,2,3-triazolines and their

The following publications discuss primarily the use of

use as a new and novel class of anticonvulsant drugs,
and more particularly relates to certain additional new

synthesis of certain anilinopyridazines and pyrazoles,

triazolines as intermediates in providing a route for the

A2-l,2,3-triazolines, their methods of preparation, and

(Kadaba, P. K., and Triplett, J. “Heterocycles, An In

compositions for their use in the treatment of convul

ternational Journal for Reviews and Communications in

sive disorders.

Heterocyclic Chemistry,” Vol. 9, No. 3, 1978, pp.

243-246) and triazoles (Kadaba, P. K. “Synthesis, Inter
BACKGROUND ART
20
national Journal of Methods in Synthetic Organic
Studies over the past 15 years suggest that the pre
Chemistry,” No. 9: Stepember, 1978, pp. 694-695.)
vailing rate of epilepsy in the United States is between 5
The following publications describe the results of
and 20 per 1000, and recent estimates drawn from popu
screening or evaluation of triazolines for pesticide and
lation surveys indicate that the higher rates are closer to

herbicide properties. (Kadaba, P. K., “Pestic. Sci,”
the true prevalence. This means that 1 to 4 million 25
1974, 5, pp. 255-258. ) (Kadaba, P. K., “Journal of Phar
Americans suffer from some form of epilepsy. For cer
maceutical Sciences,” Vol. 59, No. 8, 1970, pp. 1190-91.

tain types of seizures there are no speci?c drugs avail
able; for seizures that are controlled with currently
available therapy, a new drug may allow a reduction in

The following publications primarily describe proce

the toxic side effects. Despite these facts, between 1960 30 dures for the production of triazolines through cycload
dition of diazomethane to Schiff bases and solvent ef
and 1974, no new anticonvulsant drug was marketed in

the United States (with the exception of diazepam,

fects on this reaction as well as steric effects. (Kadaba,

1977-1978, there has been a resurgence of interest in the

erocyclic Chemistry, 6, 1969, pp. 587-589. ) (Kadaba, P.
K. “Tetrahedron, Vol. 25, 1969, pp. 3053-3066. )
(Kadaba, P. K., “Synthesis, International Journal of
Methods in Synthetic Organic Chemistry, No. 2: Febru

P. K., and Edwards, J. “Journal of Organic Chemistry,
which was marketed primarily as a minor tranquilizer)
26, 1961, pp. 2331-2335. ) (Kadaba, P. K., “Tetrahe
(Vida, J. A. “Anticonvulsants,” Academic Press, New
York, 1977). However, since the approval of carbamaz 35 dron, Vol. 22, 1966, pp. 2453-2460. ) (Kadaba, P. K.,
and Fannin, N., “Journal of Heterocyclic Chemistry,”
epine in 1974 and clonazepam in 1975, and sodium di
4, 1967, pp. 301-304. ) (Kadaba, P. K., “Journal of Het
propylacetate, eterobarb, mexiletine and others in

development of better anticonvulsant drugs for the
management of epilepsy. Also responsible for this re
newed interest is the establishment of the Anticonvul

sant Screening Project of the Antiepileptic Drug De

ary, 1973, pp. 71-84. ) (Kadaba, P. K., “Journal of Het

velopment (ADD) Program of NINCDS (National

erocyclic Chemistry, 12, 1975, pp. 143-146. ) (Kadaba,
P. K., “Joumal of Heterocyclic Chemistry, 13, 1976, pp.
1153-54. )

Institute of Neurological and Communicative Disorders
and Stroke) of NIH, in January, 1975.

45

In recent years hundreds of different heterocyclic

compounds have been synthesized and screened for
anticonvulsant activity. These include mostly ?ve and
six membered ring systems containing up to three or
four heteroatoms and seven membered ring systems 50

related to the diazepines. Among the nitrogen contain
ing heterocycles, a considerable amount of work has
been done in the areas of ?ve membered rings bearing
one or two nitrogen atoms.

In none of these publications, however, is there any
disclosure of use of any of the 1,2,3 triazoline com
pounds as anticonvulsants.
SUMMARY OF THE INVENTION

It is accordingly one object of the present invention
to provide certain triazolines as anticonvulsant drugs.

A further object of the present invention is to provide
several new A2-1,2,3-triazolines and methods for their

Five membered rings with 3 or 4 nitrogen atoms that 55 use in the treatment of convulsive disorders.
A still further object of the present invention is to
and some tetrazoles. Very little has been done on 1,2,3
provide anticonvulsant compositions containing as the
triazoles (Popp, F. D., In “Anticonvulsants,” J. A.
essential ingredient certain A2-1,2,3-triazo1ines and use
Vida, Ed. Academic Press, New York, 1977). The liter
of these triazolines as antiepileptic drugs in the treat
ature indicates that to date there are no references to 60 ment of convulsive disorders such as epilepsy.
any published work relating to studies on the anticon
Other objects and advantages of the present invention
vulsant activity of triazolines.
will become apparent as the description thereof pro
ceeds.
The 1,2,3-triazolines are a novel group of anticonvul
sant compounds because their heterocyclic ring system
In satisfaction of the foregoing objects and advan
is different from that of conventional anticonvulsant 65 tages, there is provided by this invention anticonvulsant
drugs. The presently marketed antiepileptic drugs, for
compositions comprising as the active ingredient, a
the major part, have a dicarboximide function and/or a
compound selected from those of the following formu
disubstituted quaternary carbon group (barbiturates,
lae:

have been investigated, include mostly, 1,2,4-triazoles

4,618,681
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In a further aspect of the present invention, new com

pounds are provided which have anticonvulsant activ
ity and which are of the following general formulae:

wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or

2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or
2-quinolyl, and R2 is hydrogen, m- or p-trifluoromethyl,
p-methyl, m-ch1oro-p-?uoro-, p-ethyl, p-?uoro, m- or
p-chloro, p-bromo, m-nitro, or p-COOR3, wherein R3 is

In the above formulae, R1 is Z-pyridyl, 3-pyridyl,
4-pyridyl, ortho-chlorophenyl, or ortho-nitrophenyl,

and R2 is p-fluoro, m- or p-trifluoromethyl, m-chloro-p
fluoro, p-ethyl, or m-chloro, and when R1=2,6
dichlorophenyl, R; can be p-bromo, and when R1=2
pyridyl, R2 can be hydrogen.
There is further provided by this invention methods
epilepsy including petit mal and grand mal.
for administration of the anticonvulsant composition to
There is also provided by this invention certain new
compounds which are useful as anticonvulsant drugs. 20 mammals including animals and humans.
The triazolines of this invention may be prepared by
These compounds may be characterized by the follow
lower alkyl of one to four carbon atoms.

Also provided are methods for administration of the
anticonvulsant compositions of this invention to mam
mals in the treatment of convulsive disorders such as

ing general formulae:

the reaction of diazomethane with Schiff bases as de~

scribed, for example, by Mustafa, A., (J. Chem. Soc),
234 (1949), and by Buckley, G. D., (J. Chem. Soc),
1850, (1954). Further methods of preparation involving
R]

I

1,3-dipo1ar cycloaddition reactions are described in the
applicants’ own publications in Kadaba, et al. (J. Org.

N

l

Chem., 26, 2331 (1961), by Kadaba in “Tetrahedron,”
22, 2453 (1966), by Kadaba in “Tetrahedron” 25, 3053
(1969) and J. Heterocyclic Chem, 12, 143, (1975). This
reaction proceeds generally in accordance with the

/N
N/

wherein R1 is 4-pyridyl, 3-pyridyl, 2-pyridyl, ortho
chlorophenyl, 2,6-dich1orophenyl, or ortho-nitrophe
nyl, and R2 is p-?uoro, p-bromo, rn-chloro-p-?uoro, m
or p-tri?uoromethyl, p-ethyl, m-chloro, or hydrogen.

following equation.
35

DESCRIPTION OF PREFERRED
EMBODIMENTS
As indicated above, this invention relates to certain

+ CHZNZ %

1,2,3-triazo1ines which are useful as anticonvulsants.
The triazolines of this invention are to be named as

R2

A2-l,2,3-triazolines, or as
lI-I-4,5-dihydro-l,2,3
triazoles. The triazolines of this invention are substi

R1

tuted in the l and 5 positions by aryl or heterocyclic
groups which may also contain substituents. The triazo 45
line compounds of this invention have potent to moder

ate anticonvulsant activity as antiepileptic drugs in the
treatment of convulsive disorders such as petit mal

(absence seizures) and grand mal (major motor sei

zures).
In one aspect of the invention, it relates to novel

anticonvulsant compositions which comprise as the
active ingredient a compound selected from those of the

following formulae:

N

l

l

N%

N

A2- 1,2,3-Triazolines

In the above equation R1 and R2 are as de?ned above.
Kinetic studies on solvent effects of this reaction
indicate that protic solvents such as water have a gen

eral accelerating effect on the reaction and by carrying
out the addition reaction in an aqueous dioxane solution,

high yields of triazolines are produced.
As pointed out, the triazoline compounds and result
ing anticonvulsant compositions of this invention are
useful in the treatment of convulsive disorders. The
potency of the compounds range from those which are
very potent to those of moderate potency. A series of
60 triazolines of this invention has been evaluated in Phase

I anticonvulsant screening using two seizure models in

wherein R1 is o-chlorophenyl, o-nitrophenyl, 2,4- or

2,6-dich1orophenyl, 4-pyridy1, 3-pyridyl, Z-pyridyl, or

the mouse, the maximal electro-shock seizure (MES)
test and the subcutaneous pentylenetetrazole (Met
razole) seizure threshold (scMet) test. These two meth

Z-quinolyl, and R2 is hydrogen, m- or p-trifluoromethyl, 65 ods of seizure provocation reliably elicit well character
p-methyl, m-chloro-p-?uoro, p-ethyl, p-?uoro, m- or
ized seizure phenomena (Chen. G., et al. Proc. Soc.

p-chloro, p-bromo, m-nitro, or p-COOR3, wherein R3 is

Exp. Biol. Med., 87, 334 (1954), and together have been

lower alkyl or one to four carbon atoms.

shown suf?cient to identify all compounds known to

4,618,681
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6

demonstrate anticonvulsant activity in other tests.
Based on the Phase I screening results, the compound to
be tested is placed in one of three categories. Those
failing to demonstrate anticonvulsant activity at doses
up to 300 mg/kg are considered inactive. Class II com 5
pounds show anticonvulsant activity at doses greater
than 100 mg/kg or show activity at 100 mg/kg which is
not reinforced by similar activity at 300 mg/kg. Thus

l8. l-(m-chloro-p-?uorophenyl)-

compounds of class or group I1 demonstrate anticon

As shown in the above table, the most potent com

vulsant activity without signs of neurological de?cit,

Group Classi?cation
Il

5-(3-pyridyl)

A2-l,2,3-triazoline

four compounds of Class I. In addition, compounds 7
and 12 in Class II are also effective anticonvulsant com

pounds because they give 100% protection at 600 and
300 mg/kg, respectively, without any signs of neurolog
ical de?cit. Thus, these six compounds represent the
preferred embodiments of the anticonvulsant composi
tions of this invention. Compound 9 which is l-(para
chlorophenyl)-5-(4-pyridyl)-A2-1,2,3-triazoline
and
compound 16 which is 1-(p-trifluoromethylphenyl)-5

vulsants. They demonstrate anticonvulsant activity in
either the MES test or the ScMet test, or both at doses

of 100 mg/kg or 30 mg/kg without signs of neurologi
cal de?cit and thus have an estimated protective index
of greater than 1.
The following table presents the results of these tests
with respect to certain compounds of the present inven

Anticonvulsant Activity

Compound

10 pounds are compounds 9,10,16 and 17 which are the

but do not have signi?cant potency. The Class I com
pounds are those which are most promising as anticon

tion. This Table l identi?es the speci?c compounds
tested, by chemical name and provides the anticonvul
sant activity based on classi?cation in Group I or Group

TABLE l-continued

20 (4-pyridyl)-A2-1,2,3-t1iazoline are the most preferred

compounds of this invention.
As indicated above while various preparative reac
tions are known for the triazolines of the invention, the

II.

diazo-alkane-imine reaction of the following equation 1

TABLE 1
Compound
l. l-m-tri?uoromethylphenyl-

25 and the azide-ole?n cycloaddition reaction of the fol

lowing equation 2 are generally preferred for 1,2,3
triazoline synthesis:

Anticonvulsant Activity
Group Classi?cation
II

5-(o-chlorophenyl)

A2-l,2,3-triazoline
2. l-(p-Tri?uoromelhylphenyl-

II

30

S-(o-chlorophenyD

A2-l,2,3-triazoline
3. l-(p-Ethylphenyl)
>

5-(o-chlorophenyl)

A2-l,2,3-triazoline

35

4. l-(m-Chlorophenyl)

5-(o-nitrophenyl)

A2-l,2,3-triazoline
5. l-(m-Nitrophenyl)

5-(2,4-dichl0rophenyl)

A2-l,2,3-triazoline
6. l-(p-Bromophenyl)

5-(2,6-dichlorophenyl)

A2-l,2,3-triazoline
7. l-(Phenyl)-

ll

5-(4-pyridyl)

A2-1,2,3-triazoline
8. l-(p-EthoxycarbonyD-

II

5-(4~pyridyl)

45

A2-l,2,3-triazoline
9. l-(p-Chlorophenyl)-

I

5_(4-pyridyl)

A2-l,2,3-triazoline
. l-(p-FluorophenyD-

l
R]?
R
éNN

I

5-(4-pyridyl)

A2-1,2,3-triazoline
ll.

N

l-(p-MethylphenyD

5-(4-pyridyl)

Since Schiff bases (imines) bearing a range of aro
matic or heterocyclic substituents can be readily pre

A2-l,2,3-triazoline
. l-(m-chlorophenyl)

. l-(phenyl)

5-(2-pyridyl)

A2-l,2,3-triazoline
. l-(p-ChlorophenyD

5-(2-pyridyl)

A2-l,2,3-triazoline
. l-(m-Nitrophenyl)-

II

5-(2-quinolyl)

A2-l,2,3-triazoline
. l-(p-trifluoromethylphenyl)-

I

5-(4-pyridyl)
S-(4-pyridyl)

A2-l,2,3-triazoline

ane. The reaction mixture is then allowed to stand at
15°—20° C. for 2-4 days in the case of the reactive anils

and 6-7 days in the case of the slow reactions. At the
65 end of this period, the mixture is cooled and diluted

A2-l,2,3-triazoline
. l-(m-trifluoromethylphenyl)-

pared, the CHzNz-imine reaction is particularly suited
for the synthesis of the 1,5-substituted triazolines in this
patent application. As pointed out above, this addition is
preferably carried out in aqueous dioxane solutions
according to the applicant’s previous publications. In a
60 typical preparation, the Schiff base is dissolved in a
cold, freshly prepared solution of CHzNz in wet diox
55

5-(4-pyridyl)

A2-l,2,3-triazoline

I

with water to precipitate~ the triazoline adduct.

The CHZNZ for the reaction is prepared conveniently
from N,N'-nitrosomethylurea in the same manner that

4,618,681
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8

undistilled ethereal solutions are obtained, but using
l,4-dioxane in place of diethyl ether. Dioxane is the
solvent of choice because of its easy miscibility with

TABLE 2-continued
Compound

M.pt. 'C.

Yield %

84-85

24

water and the ease with which it can be substituted for

diethyl ether. The CHZNZ solution thus obtained con
tains water in suf?cient amounts to catalyze the reaction

5-(2-pyridyl)

and is used immediately.
The Schiff bases are prepared using standard proce
dures by heating a mixture of the appropriate adehyde
and amine in ethanol or alternatively by heating the
mixture in benzene followed by azeotropic removal of

A2-l,2,3-triazoline
.

l-(p-Chlorophenyl)

S-(2-pyridyl)

A2-l,2,3-triazoline
.

l-(m-Nitrophenyh

5-(2-quinolyl)~

A3-l,2,3-triazoline

the water, the latter being a more suitable procedure in
.

dif?cult cases.

l-(p-trilluoromethylphenyl)

149-150

5-(4-pyridyl)

The anticonvulsant compounds of the present inven

A2-l,2,3-triazoline

tion may be administered to animals or humans at doses

. l-(m-trilluoromethylphenyl)

combination with about 0.001 to 2.0 wt.% of the active

68-71

42

88-91

5]

5-(4-pyridyl)

ranging from about 30 mg/kg up to about 300 mg/kg.
Preferred levels of administration range from about 30
mg/kg up to 100 mg/kg. The active ingredients or
compounds of this invention may be administered in
any desired form by injection or in the oral form. Con 20
ventional adjuvents and carriers may be employed in

A2-l,2,3-lriazoline

These compounds were identi?ed through their ele

mental analyses, characteristic melting point (they de

ingredient. Thus the anticonvulsant compositions of this
invention may be administered in pill form or by injec
tion. As indicated above, the dosage rate ranges from
about 30 mg/kg up to about 300 mg/kg.
The following examples are presented to illustrate the

compose at their melting point with vigorous evolution
of nitrogen), and NMR spectra, which exhibits an ABC
pattern in the 4.5 to 5.0 ppm region for the three protons
at positions 4 and 5.
These compounds were then evaluated in accordance
with the methods set forth above for anticonvulsant

invention but it is not to be considered as limited

thereto. In the examples and throughout the speci?ca
tion, parts are by weight unless otherwise indicated.

characteristics. The results are set forth in Table 1
above. As pointed out with respect to Table l, the com

EXAMPLE 1

pounds demonstrate anticonvulsant activity in either

Using the reaction of Equation 1 described above
involving cycloadditions of diazoalkanes to imines
(Schiff bases), the following compounds were prepared.
In the following Table 2, melting points and yields are
given for new compounds prepared.

the MES test or the scMet test or both. Compounds of

Class I demonstrate this activity at doses of 100 mg/kg
or 30 mg/kg without signs of neurological de?cit and
thus have an estimated protective index of greater than
1.
EXAMPLE 2

TABLE 2
Compound
l. l-m-tri?uoromethylphenyl-

M.pt. “C.

Yield %

49-51

77

One of the compounds, compound 9 which is l-(para
chlorophenyl)-5-(4-pyridyl) A2-l,2,3-triazoline, was
evaluated for further study to provide additional infor

83-86

80

ity.

44-46

48

40

5-(o-chlorophenyl)

A2-l,2,3-triazoline
2. 1-(p-Tri?uoromethylphenyl

mation as to its general pro?le of anticonvulsant activ

5-(o-chlorophenyl)

45

A2-l,2,3-triazoline
3. l-(p-Ethylphenyl)v

5-(o-chlorophenyl)

(MES) activity at 300 mg/kg and anti-Metrazol activity

A2-l,2,3-triazoline
4. l-(m-Chlorophenyl)

5-(o-nitrophenyl)

90-92

60

156

75

at 100 mg/kg. Rotorod toxicity was not seen in animals

given up to 300 mg/kg of the test substance. Four hours
after administration, the compound was ineffective by
the MES test (although the tonic extension was slow) at
300 mg/kg; however, anti-Metrazol activity was pres
ent at this dose level. Thus, the pro?le of anticonvulsant

A2-l,2,3-triazoline
5. l-(m-NitrophenyD

5-(2,4-dichlorophenyl)

A2-l,2,3-triazoline
6. l-(p-Bromophenyl)

5-(2,6-dichlorophenyl)

A2-l,2,3~triazoline

activity of compound 9 was characterized by the ability
55 to modify maximal electroshock seizure pattern and to

7. l-(Phenyl)

elevate the Metrazol seizure threshold in nontoxic
doses. Accordingly, the compound was subjected to

5-(4-pyridyD

A2-l,2,3-triazoline

Phase II Anticonvulsant Quanti?cation in Mice i.p.,
Phase III Toxicity Pro?le in Mice i.p., Phase IV Anti
convulsant Quanti?cation in Mice p.o., Phase V Antiep~
ileptic Drug Differentiation in Mice i.p., and Phase VI

8. l-(p-EthoxycarbonyD

5-(4-pyridyl)

A2-l,2,3-triazoline
9. l-(p-Chlorophenyl)

5-(4-pyridyl)

Anticonvulsant Quanti?cation in Rats p.o. The results
obtained provided the basis to compare the anticonvul
sant activity and toxicity of compound 9 with those of

A2-1,2,3-triazoline
. l-(p-Fluorophenyl)

139-141

5-(4-pyridyl)

72

A2-l,2,3-tn'azoline

65

. l-(p-Methylphenyl)

5-(4-pyridyl)

A2-l,2,3-triazoline
. l-(m-chlorophenyl)

Thirty minutes after administration, compound 9 of
this invention exhibited anti-maximal electroshock

109-110

80

clinically useful antiepileptic drugs.
In this experiment male albino mice (CF No. 1 strain;
18 to 25 g wt) obtained from Charles Rivers, Wilming
ton, Mass., and male albino rats (Sprague Dawley, 100

4,618,681
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to 150 g wt) obtained from Simonsen, Gilroy, Calif.,

10

were used as experimental animals. All animals were

neurotoxic dose (TD50) was determined by the rotorod
procedure at the time of peak neurotoxic effect. When a

allowed free access to both food (S/L Custom Lab
Diet-7) and water, except when they were removed

diameter rotating at a speed of six rpm it can maintain its

normal mouse is placed on a knurled rod one inch in

from their cages for the experimental procedure.

equilibrium for long periods of time. Neurological de?

Compound 9 was compared with four prototype

cit is indicated by inability of the mouse to maintain its
equilibrium for one minute in each of three trials on this

antiepileptic agents (phenytoin, phenobarbital, ethosux
imide, and valproate). Compound 9 was administered in

rotating rod. Neurological de?cit in rats is indicated by

the requisite volume of 30% polyethylene glycol 400;
whereas phenytoin, phenobarbital, ethosuximide, and

ataxia, loss of placing response and muscle tone. Se

condly, the overt signs and symptoms of toxicity in

valproate were administered in 0.9% sodium chloride
solution. The drugs were administered either orally or
intraperitoneally in a volume of 0.01 ml/g body weight

duced by each prototype agent and test substance were

various doses of the drug until at least four points were
established between the limits of 100% protection or

of the HDSO and LD50. The HDSO represents the me

four chemical. The electrical test employed was the
maximal electroshock seizure pattern test. This test
measures the ability of the test drug to abolish the hind

a 0.027% solution; the solution was used 15 to 45 min
utes after preparation. Metrazol (3.5%) was adminis

determined by giving two mice either 1TD50, 2TD50’s,
or 4TD50’s and observing and testing them 10, 20, and
in mice and 0.04 ml/lO g in rats. All tests were con
30 minutes and 1, 2, 4, 6, 8, and 24 hours after drug
ducted at the previously determined time of peak drug 5 administration for the onset, intensity, and type of overt
effect. To determine anticonvulsant potency and toxic
toxicity. These observations also provide preliminary
ity, groups of at least eight mice or rats were tested with
information essential for the subsequent determination
dian dose at which 50% of animals lose their righting
toxicity and 0% protection or toxicity. The dose of drug 20 reflex. The 24~hour LD50 represents the median dose
required to produce the desired endpoint in 50% of
which causes death in 50% of the animals within 24
animals (EDSO) in each test, the dose eliciting evidence
hours.
of minimal neurological toxicity in 50% of animals
Except for bicuculline, all convulsant drugs (Metra
(TD50), the 95% con?dence interval, the slope of the
zol, picrotoxin, and strychnine) administered to mice
regression line, and the SE. of the slope were then 25 were dissolved in suf?cient 0.9% sodium chloride solu
calculated by means of a computer program written by
tion to make a concentration of 0.85%, 0.032%, and
NINCDS.
0.012%, respectively. Bicuculline was dissolved in 1 ml
The pro?le of anticonvulsant activity for each sub
of warmed 0.1N HCl with the aid of a micro-mixer and
stance was established by ?ve tests: one electrical and
suf?cient 0.9% sodium chloride solution added to make
tered to rats in a solution of 0.9% sodium chloride.

limb tonic-extensor component of maximal seizures
induced in mice by 50 mA of current delivered for 0.2

All convulsants were administered subcutaneously
into a loose fold of skin on the back of the neck in a

seconds or in rats at 150 mA of current delivered for 0.2 35 volume of 0.01 ml/g body weight in mice; Metrazol was

seconds; this amount of current is approximately six
times the threshold and reveals the ability of the test
substance to prevent seizure spread. The four chemical

injected in a volume of 0.02 ml/ 10 g body weight in
rats. The convulsant drugs were administered at the

previously determined time of peak anticonvulsant ac

tests include the subcutaneous Metrazol Seizure

Threshold Test (sc Met Test), subcutaneous Bicuculline
Seizure Threshold Test (sc Bic Test), subcutaneous
Pierotoxin Seizure Threshold Test (sc Pic Test), and the
subcutaneous Strychnine Seizure Pattern Test (sc
Strych Test). Except for the sc Strych Test, these tests

40

tion of the drug under study. Except for picrotoxin
treated animals, the mice (eight animals/group) were
then observed for at least 30 minutes for the presence or

absence of a seizure. The animals treated with picro
toxin were observed for periods of 45 to 60 minutes for
the presence or absence of a seizure. Except for strych
measure the ability of anticonvulsants to afford com 45 nine, absence of a ?ve-second episode of clonic spasms
plete protection against threshold seizures induced by
(threshold seizure) was taken as protection. In the case

the subcutaneous injection of the CD97 of the convul

of strychnine, complete abolition of the hindleg tonic

sant agent. The so Strych Test measures the ability of
the test substance to abolish all tonic components of

extension was taken as protection.

The results obtained in Phase II Anticonvulsant

seizures induced by the subcutaneous injection of the 50 Quanti?cation studies in mice i.p., are shown in Table 3.
CD97 of strychnine. The sc CD97 of Metrazol, bicucul

It may be seen from the table that the times of peak

line, picrotoxin, and strychnine in mice is 85, 2.70, 3.15,

effect (TPE) of the ?ve compounds range from 15 min
and 1.20 mg/kg, respectively; the sc CD97 for Metrazol
utes to 6 hours; except for phenytoin (2 hours by all
in rats is 70 mg/kg.
tests) and compound 9 by the rotorod test (6 hours), the
The pro?le of toxicity for each test drug was estab 55 TPE’s of the remaining substances vary from 15 min
lished by the following procedures: ?rstly, the minimal
utes to one hour.
TABLE 3
PROFILE OF ANTICONVULSANT ACTIVITY OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time
of
Rotorod

Substance

Test
(hrs)

TD50
(mg/kg)

EDSO (mgékg! and PI
MES
sc Met

1132.85

257.42

(97045-133328)
[7.92]

(235.75-297.53)
[12.88]

4.40‘

Compound 9

6A,!

26.02‘
43.53

(39.00-49.96)
[8.75]

4,618,681
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TABLE 3-continued
PROFILE OF ANTICONVULSANT ACTIVITY OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time
of
Rotorod
Test
TD50
ED50 m /k )and PI
Substance
(hrs)
(mg/kg)
MES
sc Met
6.89

Phenytoin

2,2,2

<0.22

65.46

9.50

(52.49-72.11)

(813-1044)

No Protection

[15.23]

[13.66]

up to 300
3.17

Phenobarbital

1,1,1

5.24

69.01

21.78

13.17

(62.84-72.89)

(14.99-25.52)

(587-1593)

[24.67]

[14.98]

[5.93]
<O.44

3.38

440.83

Ethosuximide

5,5,3

130.35

(38309-48534)

No Protection

(11099-15045)

[18.37]

up to 1000

[10.06]
1.57

valproate

1,4,1

2.87

425.84

271.66

148.59

(36891-45040)
[20.84]

(24697-33789)
[12.83]

(12264-17702)
[11.85]

( ) 95% Con?dence interval

[ ] Slope. regression line
‘Protective Index (P.I.) = TDSO/EDSO

With respect to anticonvulsant activity, phenobarbi
tal, the compound of this invention, and valproate had

active by the sc Met test range from 2.87 for valproate
to 26.02 for the compound of this invention. Phenobar
signi?cant anticonvulsant activity in nontoxic doses as
bital and ethosuximide were also effective by the sc Met
measured by both the maximal electroshock seizure 30 test with P.I.’s of 5.24 and 3.38, respectively.

(MES; ED50’s 21.78, 257.42, and 271.66 mg/kg, respec
tively) and subcutaneous Metrazol seizure (sc Met;
EDSO’s 13.17, 43.53, and 148.59 mg/kg, respectively)

Phase III, Toxicity Pro?le Studies in Mice given
1TD50, 2TD50’s, and 4TD50’s of Compound 9 intra~
peritoneally, were also carried out on the compounds.

tests. In contrast to the above, phenytion had signi?cant
The toxicity pro?le induced by Compound 9 was char
anti-MES activity (ED50, 9.50 mg/kg) but did not pro 35 acterized by decreased motor activity, ataxia, decreased
tect against subcutaneous Metrazol seizures. Ethosuxi
respiration and cyanosis. In addition to these symptoms,
mide, on the other hand, was not able to protect against
one of two animals given 4TD50’s displayed rotorod
maximal electroshock seizures but had signi?cant anti
toxicity. Both mice given 4TD50’s of Compound 9
Metrazol activity in nontoxic doses (ED50, 130.35
were dead 24 hours after drug administration. One of
mg/kg).

'

40 two animals given 2TD50’s was still ataxic and cyanotic

With regard to minimal neurotoxicity, the compound
of this invention was the least toxic (TD50, 1132.85

mg/kg); however, 3 of 8 animals given 1300 mg/kg and
5 of 8 animals given 1500 mg/kg were dead 24 hours

after the administration of compound 9. Phenytoin and

45

phenobarbital were the most toxic with TD50’s of 65.46

and 69.01 mg/kg, respectively. Ethosuximide and val
proate were equitoxic and induced minimal neurologi
cal de?cit in 50% of mice at doses of 440.83 and 425.84

mg/kg, respectively.

50

It may also be seen from Table 3 that the protective

indices (TD50/ED50=P.I.) by the MES test range
from <O.44 for ethosuximide to 6.89 for phenytoin. The

at the end of 24 hours. A detailed qualitative description
of the pro?le of acute toxicity in mice (i.p.) of Com
pound 9 as well as phenytoin, phenobarbital, ethosuxi
mide, and valproate is shown in Table 4. As shown in
Table 4, the hypnotic dose 50 (HDSO) and lethal dose 50
(LDSO) of Compound 9 were 2050.56 and 2132.00
mg/kg, respectively. Thus, the HDSO and LDSO for
Compound 9 were signi?cantly higher than those for
either phenobarbital (135.45 and 264.70 mg/kg, respec

tively), phenytoin (178.34 and 229.61 mg/kg, respec
tively), or valproate (885.33 and 1104.62 mg/kg, respec
tively). The HD50 of Compound 9 was higher than that
for ethosuximide (2050.56 vs 850.61 mg/kg), whereas

P.I.’s of the remaining three compounds (compound 9
the LDSO’s were not signi?cantly different (2132.00 vs
of this invention, phenobarbital, and valproate) are 4.40, 55 1752.23 mg/kg).
3.17, and 1.57, respectively. The P.I.’s of compounds
TABLE 4
PROFILE OF ACUTE NEUROTOXICITY
OF INTRAPERITONEALLY ADMINISTERED NO. 9 AND SOME PROTOTYPE
ANTIEPILEPTIC DRUGS IN MICE
HDSO
LDSO‘

Pro?le of Acute Toxicity, Mice i.p.
Name

1 X TDSO

2 X TDSO

4 X TDSO

Compound

(1133 mg/kg) Both animals

(2266 mg/kg) Both animals were

(4532 mg/kg) Both animals had

9

were ataxic beginning at 10
min. One animal had decreased
motor activity at 20 min and
both had decreased motor

ataxic beginning at 10 min.
They exhibited decreased respiration with cyunosis beginning
at 30 min and decreased motor

ataxia and decreased respiration beginning at 10 min. One
animal had decreased motor
activity and rotorod toxicity

(mg/kg)

2050.56
(1591.47-322868)
[4.27]
2132.00

4,618,681
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TABLE 4-continued
PROFILE OF ACUTE NEUROTOXICITY
OF INTRAPERITONEALLY ADMINISTERED NO. 9 AND SOME PROTOTYPE
ANTIEPILEPTIC DRUGS IN MICE

.1252.

Pro?le of Acute Toxicity, Mice i.p.
Name

Phenytoin

1 X TDSO

2 X TDSO

LD50‘

4 X TD5O

(mg/kg)

activity and respiration with

activity beginning at 2 hrs.

with cyanosis at 10 min. The

(1666.11-3368.10)

cyanosis at 2 hrs. Both
appeared normal at 24 hrs.

One animal appeared normal at 24
hrs while the other remained

other animal had decreased
motor activity at 2 hrs. Both

[4.45]

ataxic and cyanotic at 24 hrs.

animals were dead at 24 hrs.

(65 mg/kg) lncreased motor
activity, slight ataxia, frequent grooming, nervous behavior, and straub tail,

(130 mg/kg) Mild ataxia,
periods of sedation, spasms of
arching, rolling, straub tail,
ptosis, and respiratory de-

(260 mg/kg) Toxic manifestations identical to ZXTDSO. At
1 hr, righting re?ex absent,
longer periods of sedation,

178.34
(152.93—195.45)
[14.03]

animals were not toxic by the
rotorod test.

pression. Later, spasms reduced and sedation increased.
At 24 hrs, toxicity present,

and spasms reduced to head
twisting and uncoordinated
movements; respiratory de-

229.61
(21644-25910)
[15.89]

other symptoms less pronounced.

pression continued, mice dead
at 24 hours.

Phenobarbital

(70 mg/kg) Ataxia with increased motor activity followed
by sedation and ptosis with
one of two animals toxic by
the rotorod test up to 4 hrs.

(140 mg/kg) Ataxia with increased motor activity followed

(280 mg/kg) Ataxia with increased motor activity follow-

by loss of righting re?ex,

ed by loss of righting re?ex,

tremors, re?ex scratching,
ptosis, sedation and some

tremors, re?ex scratching,
ptosis, sedation, anesthesia

respiratory depression. Both
mice regained their righting

with analgesia and respiratory
depression. Both animals

re?ex at 2 hrs and one of two

became cold to touch and

was still toxic by the rotorod
test at 8 hrs.

cyanotic with increased res
piratory depression; death
occurred at approximately 3
and 6 hrs.

Etho-

(440 mg/kg) Uncoordinated

(880 mg/kg) Uncoordinated

(1760 mg/kg) Uncoordinated

suximide

motor activity, re?ex scratch-

motor activity, re?ex scratch-

motor activity, respiratory

ing, respiratory depression,

ing, loss of righting re?ex

depression, hypnosis and

ataxia.

at 4 mins but regained in 20

anesthesia followed at later

mins, hypnosis followed at

time intervals by cyanosis

later time intervals by seda-

and death at 24 hrs.

135.45
(11490-17742)

[8.41]
264.70

(24155-28552)
[15.95]

850.61
(751.19-91793)

[16.43]
1752.23
(160702486664)

tion, ataxia, ptosis, vasodila-

[14.75]

tion and diarrhea.

Valproate

(400 mg/kg) Mild ataxia, with

(800 mg/kg) Ataxia, with both

(1600 mg/kg) Both animals died.

885.53

one of two mice toxic by the

animals toxic by the rotorod

(At 3XTD50 there was respira-

(82086-95704)

rotorod test. Appeared

test, normal respiration and

tory depression, ptosis, hyp-

normal at the end of 4 hrs.

some sedation. Both animals
appeared nonnal at 4 hrs.

nosis but no analgesia. These
animals were dead at 4 hrs.)

[12.46]
1104.62

(l021.54-l253.66)

[11.41]
'24 hour period

The anticonvulsant activity and minimal neurotoxic
dose (TDSO) upon oral administration were determined

by Phase IV studies, Anticonvulsant Quanti?cation in 45 ate was the least potent (EDSO, 388.31 mg/kg). The
Mice p.o. The TPE of Compound 9 after oral adminis
other two compounds (Compound 9 and ethosuximide)
tration was one-half hour by the anticonvulsant tests; 24
were equally potent by the scMet test with ED50’s of
hours was used as the TPE by the rotorod test. The

152.56 and 192.71 mg/kg, respectively.

TPE by the rotorod test was signi?cantly different from
By the oral route of administration in mice, ethosuxi
that obtained after intraperitoneal administration of test 50 mide and valproate were essentially equitoxic (TD50’s,

Compound 9 (24 hours and six hours, respectively).
Except for valproate, the four prototype agents exhib

879.21, and 1264.39 mg/kg, respectively). Phenytoin
and phenobarbital were the most toxic with quite simi

ited TPE’s that were probably not signi?cantly differ
lar TDSO’s (86.71 and 96.78 mg/kg, respectively). Com
ent from those observed after the intraperitoneal admin
pound 9 was somewhat more toxic than ethosuximide
istration of these agents. Valproate had a TPE of one to 55 with a TDSO of 704.92 mg/kg; however, several deaths
two hours after oral administration vs one-fourth hour
occurred within the dose-range selected for the rotorod
after intraperitoneal administration.
regression line (600 and 800 mg/kg, 1 of 8 died; 700 and
With respect to anticonvulsant activity as measured
1000 mg/kg; 6 and 4 of 8 died).
by the MES test, phenytoin was again the most potent
The P.I. for Compound 9 is 2.42 by the MES test,
(EDSO, 9.04 rug/kg), whereas valproate was the least 60 whereas the P.I.’s for phenytoin, phenobarbital, etho

potent (ED50, 664.80 nag/kg). Compared to phenytoin,

suximide, and valproate are 9.59, 4.82, <0.44, and 1.90,
respectively. The R1. for Compound 9 by the scMet
test is 4.62; whereas those for phenytoin, phenobarbital,
other hand, was 1/15 and 1/ 32 as potent as phenobarbi
ethosuximide, and valproate are <0.29, 7.69, 4.56, and
tal and phenytoin, respectively, with an EDSO of 290.72 65 3.26, respectively. Thus, the R1. for the Compound 9
mg/kg. When evaluated by the subcutaneous Metrazol
substance by the MES test compares very favorably
threshold test after oral administration, phenobarbital
with the R1. for valproate (2.42 and 1.90, respectively),
was the most potent (ED50, 12.59 mg/kg) and valpro
whereas the PI. for Compound 9 by the scMet test

phenobarbital was somewhat less potent by the MES
test (EDSO, 20.09 mg/kg). The test Compound 9, on the

115

4,618,681
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(4.62) is higher than that for either ethosuximide (4.56)
With regard to neurotoxicity, phenobarbital was the
or valproate (3.26).
most toxic (61.09 mg/kg) and ethosuximide and phenyt
The results obtained in Phase V evaluation, Antiepi
oin the least toxic (TD50’s, 1012.31 and >3000 mg/kg,
leptic Drug Differentiation in Mice, indicated that the
respectively). Valproate and Compound 9 were one
pro?le of anticonvulsant activity of Compound 9 is 5 ?fth to one-sixth as toxic as phenobarbital with TDSO’s
characterized by its effectiveness by the sc Bic and se
of 280.26 mg/kg and 393.74 mg/kg, respectively.
Met tests and its lesser effectiveness by the sc Pic test.
In summary of the above results, for Compound 9 and
Thus, its pro?le resembled that of phenobarbital and
the four prototype agents after intraperitoneal adminis
valproate to a certain extent; all three were effective
against sc Met, sc Bic, and sc Pic in nontoxic doses. In
contrast to Compound 9 which was not effective

against sc Strych, phenobarbital and valproate were

effective against strychnine; valproate in nontoxic

tration in mice and oral administration in mice and rats,
it may be stated that, in terms of the pro?le of anticon

vulsant activity, Compound 9 is somewhat similar to
that for phenobarbital and valproate. Unlike phenobar
bital and valproate, Compound 9 is ineffective after i.p.

doses, whereas phenobarbital had to be given in toxic
administration in mice by the sc Strych test, whereas
doses in order to protect against this chemical convul 15 phenobarbital is effective in toxic doses and valproate is
sant. Phenytoin, on the other hand, was ineffective

effective in nontoxic doses by this test. In terms of roto

against Metrazol, bicuculline, and picrotoxin and was

rod toxicity, Compound 9 is only one-third as toxic as
only capable of providing protection in 50% of animals
ethosuximide and valproate in this species. After oral
given strychnine. Ethosuximide was effective by the sc
administration, Compound 9 is signi?cantly more neu
Met, sc Bio, and sc Pic tests, and only protected a maxi 20 rotoxic in rats than it is in mice; there is no signi?cant
mum of 62% of animals by the sc Strych test. However,
difference in the anticonvulsant potency of this sub
ethosuximide had to be given in toxic doses to protect
stance by the MES and so Met tests in the two species.
against sc Bic seizures. It should also be noted that the
It should be noted that phenytoin administered orally in
P.I.’s for Compound 9 against sc Met and so Bic are ?ve
higher doses is absorbed only to a limited extent from
and ?fty times higher, respectively, than those for phe 25 the gastrointestinal tract of rats. Consequently, no mini
nobarbital; the RI. for Compound 9 by the sc Pic test
mal neurotoxicity was observed in this species even in
compares favorably with those for phenobarbital, etho
doses up to 3000 mg/kg.
, suximide, and valproate.

The quantitative toxicity pro?les after intraperitoneal

In Phase VI studies, Anticonvulsant Quanti?cation in

administration of Compound 9 and the four prototype
Rats p.o., it was found that the TPE for Compound 9 in 30 agents in mice are summarized in the following Table 5.
this species after oral administration was six hours by
It may be seen that the time of peak toxicity for Com
the toxicity, MES, and so Met tests. The TPE of the
pound 9 by the rotorod and righting reflex tests are 6

other four compounds ranged from one-half hour for
valproate to ?ve hours for phenobarbital.

and 24 hours, respectively, whereas those for phenytoin

administration in rats, phenobarbital was the most po
tent by the MES test (ED50, 9.14 mg/kg), whereas
Compound 9 and valproate were the least potent

reflex tests range from one-fourth to one hour. This

are 2 and 12 hours, respectively. The TPE for the other
With respect to anticonvulsant activity, after oral 35 three prototype agents by the rotorod and righting

table also shows that the LDSO/HDSO and
LDSO/T D50 ratios for Compound 9 are 1.04 and 1.88,
(EDSO’s, 265.76 and 489.54 mg/kg, respectively). The
respectively. Thus, the ratios between either the mini
ED50 of phenytoin by this test was 29.82 mg/kg. When 40 mal toxic dose and the 24-hour lethal dose or the loss of
compared on the basis of the sc Met test, phenobarbital
righting re?ex dose and the 24-hour lethal dose for
was the most potent (ED50, 11.55 mg/kg) and Com
Compound 9 are lower than those for any of the four
pound 9 and valproate were the least potent (EDSO’s,
candidate substances; hence, it would appear that the
278.13 and 179.62 mg/kg, respectively). Ethosuximide
margin between the minimal toxic dose and the 24-hour
was somewhat less potent than phenobarbital by this 45 lethal dose is probably not satisfactory.
test with an ED50 of 53.97 mg/kg.

TABLE 5
QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time
of
Test
Dose 50 (mg/kg)

Substance

(hrs)

Lethality

Righting Re?ex

Rotored

2132.00

2050.56

1132.85

(1666.11—3368.10)

(1591.47-322868)

(97045-133328)

14-45]

[4.27]

[7.92]

1.04‘

Compound 9

24,24,6

1.88‘

1.29

Phenytoin

24,12,2

3.51

229.61

178.34

65.46

(21644-25910)
[15.89]

(15293-19545)
[14.03]

(52.49-92.11)
[15.23]

264.70

135.45

69.01

(24155-28552)
[15.95]

(11490-17742)
[8.41]

(62.84-72.89)
[24.67]

1752.23

850.61

440.83

(1607.02-1866.64)
[14.75]

(751.19-91793)
[16.43]

(38309-48534)
[18.37]

1.95

Phenobarbital

24,1,1

3.84

2.06

Ethosuximide

24,1,5

3.98

4,618,681
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TABLE 5-continued
QUANTITATIVE TOXICITY PROFILE OF
INTRAPERITONEALLY ADMINISTERED COMPOUND 9 AND
SOME PROTOTYPE ANTIEPILEPTIC DRUGS IN MICE
Time
of
Test
Dose 50 (mg/kg)

Substance

(hrs)

Lethality

Righting Re?ex

Rotored

1104.62

885.53

425.84

(1021.54-l253.66)
[1 1.41]

(82086-94704)
[12.46]

(36891-45040)
[20.84]

1.25

Valproate

24.1,}

2.59

( ) 95% Con?dence interval

[ ] Slope, regression line
‘Ratio LDSO/HDSO or LDSO/I‘DSO

In conducting these tests, it was noted that Com
pound 9 is very insoluble and difficult to inject. Conse
quently, it was necessary to administer the high doses

that the test Compound 9 is adequately absorbed in mice
after oral administration.
For a candidate antiepileptic substance to be useful in

required for the righting re?ex and 24-hour lethality

the treatment of seizure disorders, its experimental pro
?le of action should compare favorably with that of

tests in mice in double the volume. In view of this fact,
additional studies were done to determine the effect of

clinically useful antiepileptic drugs. Such a comparison
this double volume on the time of peak effect of the test
should
include not only the anticonvulsant ef?cacy
substance. These studies indicated that the TPE may 25
(EDSO), but also the selectivity of toxic and anticonvul
actually be between 12 and 20 hours. For example, after
sant effects (slope of the dose-effect regression line),
toxicity (LDSO, HDSO, and TDSO), protective indices

the intraperitoneal injection of 1132 mg/kg in mice, 2, 4,
5, 4, and 3 of 8 animals were toxic by the rotorod test 6,

l2, 18, 20, and 24 hours, respectively, after administra

(TDSO/EDSO), safety ratios (TD3/ED97), absorption

Examination of the peritoneal cavity of these animals

?ve-day LDSO/EDSO). An analysis of the data for

tion of the test substance. Moreover, 1, 3, and 4 of the 8 30 characteristics (oral ED50/i.p. EDSO and oral
TD50/i.p. TD50) and the margin of safety (single dose
mice were dead at 20, 40, and 46 hours, respectively.

Compound 9, phenobarbital, ethosuximide, and valpro

revealed an unevacuated stomach that was approxi

ate reveals that Compound 9 compares very favorably
intestine; and a vermiform appendix markedly enlarged 35 with the prototype agents. Moreover, the analysis also
shows the relative merits and the disadvantages of
from flatus. Rats given 400 mg/kg of the test substance
Compound 9 compared to phenobarbital and valproate.
either orally or intraperitoneally presented similar but
mately three times normal size; an empty, ?accid small

The merits of the compound are the high P.I.’s derived
from the sc Met and so Bic tests, the high safety ratios

somewhat milder gastrointestinal symptoms. This cur
sory gross examination suggests there may be some
" relation between these gross abnormalities and the onset 40

of toxic symptoms and death. Accordingly, additional
pharmacokinetic and pharmacodynamic studies will be

in mice (TD3/ED97; MES, 1.13; sc Met, 3.44) and the
high 24-hour LD50/ED50 safety ratio by the sc Met
test. The disadvantages are related to a lack of selectiv

ity (?at regression lines) by the 24-hour lethality and so

done in order to reveal mechanisms that may contribute

Pic tests and the ‘unfavorable ratios (24-hour
low ratio between the minimal-toxic dose and the 24 45 LDSO/HDSO and 24-hour LDSO/TD50).
The invention has been described herein with refer
hour lethal dose.
ence to certain preferred embodiments. However, as
The effect of slope on the safety ratio (TD3/ED97) of
obvious variations thereon will become apparent to
Compound 9, phenobarbital and valproate indicates
those skilled in the art, the invention is not to be consid
that after the intraperitoneal administration of nontoxic
doses, the test substance (Compound 9) will protect 50 ered as limited thereto.
I claim:
97% of mice subjected to either the MES or sc MET
1. A compound of the following formula:
test. After oral administration of the test substance in
nontoxic doses, the same level of protection is obtained
only in mice subjected to the MES test. In this regard,

to the long TPE for neurotoxicity and the abnormally

Compound 9 resembles phenobarbital more closely
than it does valproate. Moreover, it should be noted

55

that Compound 9 and the prototype agents used for
comparison of the safety ratios do not provide 97%
protection by the MES and so Met tests in nontoxic
doses after oral administration in rats.
For a candidate drug to be useful in man, it should be
adequately absorbed after oral administration. The ex
tent of oral absorption can be determined from the ratio
of the oral ED50/i.p. EDSO, and should be equal to or
less than 4 for adequate absorption. In mice the oral 65

TD50/i.p. TDSO and oral ED50/i.p. EDSO ratios for
Compound 9 are 0.62, 1.13 and 3.50, by the rotorod,
MES, and $0 Met tests, respectively, which suggests

KIT
Nl
N/
/

N

wherein R1 is 4-pyridyl, 3-pyridyl, Z-pyridyl, or ortho

chlorophenyl, and R2 is hydrogen, p-fluoro, m-chloro
p-fluoro, m- or p-trifluoromethyl, p-ethyl, or m-chloro,

and when R] is orthochlorophenyl, R1 is tri?uoro
methyl, and when R; is hydrogen, R1 is Z-pyridyl.
2. A compound according to claim 1 wherein R1 is

ortho-chlorophenyl and R2 is meta-tri?uoromethyl.
3. A compound according to claim 1 wherein R1 is

ortho-chlorophenyl and R2 is para-trifluoromethyl.

4,618,681
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4. A compoundaccording to claim 1 wherein R1 is

Compounq accofding to Claim 1 wherein R1 is
4-pyr1dyl and R215 p-tri?uoromethyl.

4_pyridy1 and R2 is para_?uoro_
.

.

.

20

7

.

8_ A compound according to claim 1 wherein R1 is

5. A compound according to claim 1 wherein R1 is
4_pyridyl and R2 is m_tl_i?uommethyl‘
4'PY1'idYl and R2 is meta'chloro9. A compound according to claim 1 wherein R1 is
LII
6‘ A compound according to claim 1 wherein R1 is
3_pyridy1 and R2 is m-chloro-p-?uoro.
2-pyridyl and R2 is hydrogen.
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